Polymyositis Market Report 2026

Polymyositis Market Overview

• Polymyositis market size has reached to $1.74 billion in 2025 • Expected to grow to $2.34 billion in 2030 at a compound annual growth rate (CAGR) of 6% • Growth Driver: Rising Prevalence Of Autoimmune Diseases Driving Growth In The Market Due To Increasing Diagnosis Rates And Advancements In Treatment Options • Market Trend: Advancements In Stem Cell Therapy For Autoimmune Diseases • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Polymyositis Market?

Polymyositis is a chronic inflammatory myopathy characterized by progressive muscle weakness, primarily affecting the skeletal muscles. It results from an autoimmune response where the body's immune system mistakenly attacks muscle fibers, leading to inflammation, degeneration, and weakness. The main types of polymyositis are idiopathic polymyositis, dermatomyositis, inclusion body myositis, and overlapping myositis syndromes. Idiopathic polymyositis is a rare muscle disease that causes weakness and inflammation and is treated with corticosteroids. It is diagnosed through various methods, including physical examination, muscle biopsy, electromyography (EMG), blood tests, and magnetic resonance imaging (MRI). Treatments for the condition include immunosuppressants, immunoglobulins, corticosteroids, alkylating agents, monoclonal antibodies, and other drugs. These treatments are distributed through various channels, such as offline, online, and are used by different end users, including hospital pharmacies, online pharmacies, and retail pharmacies.

What Is The Polymyositis Market Growth Forecast?

The polymyositis market size is expected to see strong growth in the next few years. It will grow to $2.34 billion in 2030 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to growing development of targeted immune therapies, increasing integration of precision diagnostics, rising use of biologics and immunoglobulins, expansion of personalized treatment strategies, growing research into autoimmune disease mechanisms. Major trends in the forecast period include increasing use of immunosuppressive therapies, rising adoption of monoclonal antibody treatments, growing focus on accurate differential diagnosis, expansion of advanced diagnostic imaging, enhanced patient monitoring protocols.

Global Polymyositis Market Segmentation

1) By Type: Idiopathic Polymyositis, Dermatomyositis, Inclusion Body Myositis, Overlapping Myositis Syndromes 2) By Diagnosis: Physical Examination, Muscle Biopsy, Electromyography (EMG), Blood Tests, Magnetic Resonance Imaging (MRI) 3) By Treatment: Immunosuppressant, Immunoglobulins, Corticosteroids, Alkylating agents, Monoclonal Antibodies 4) By Distribution Channel: Offline, Online 5) By End User: Hospital pharmacy, Online pharmacy, Retail pharmacy Subsegments: 1) By Idiopathic Polymyositis: Immune-Mediated Polymyositis, Virus-Associated Polymyositis 2) By Dermatomyositis: Classic Dermatomyositis, Amyopathic Dermatomyositis, Juvenile Dermatomyositis 3) By Inclusion Body Myositis: Sporadic Inclusion Body Myositis, Hereditary Inclusion Body Myopathy 4) By Overlapping Myositis Syndromes:Polymyositis with Systemic Lupus Erythematosus (SLE), Polymyositis with Rheumatoid Arthritis (RA), Polymyositis with Systemic Sclerosis, Polymyositis with Mixed Connective Tissue Disease (MCTD)

What Are The Drivers Of The Polymyositis Market?

The increasing prevalence of autoimmune diseases is expected to propel the growth of the polymyositis market going forward. Autoimmune diseases refer to medical conditions in which the body's immune system mistakenly attacks its own healthy cells, tissues, or organs, leading to inflammation and damage. The prevalence of autoimmune diseases is increasing as certain genetic variants can lead to an overactive immune response, making individuals more susceptible to mistakenly attacking their own tissues. This genetic susceptibility, combined with environmental triggers such as infections, stress, and lifestyle factors, contributes to the rising incidence of autoimmune conditions. Polymyositis enhances the understanding of autoimmune diseases by demonstrating how immune system dysfunction leads to muscle inflammation, offering insights into underlying mechanisms and potential treatments for related conditions. For instance, in February 2024, according to Arthritis Australia, an Australia-based charitable not-for-profit organisation advocating for people with arthritis and musculoskeletal conditions, by 2025, approximately 562,378 Australians are living with rheumatoid arthritis (RA), accounting for 14% of the total arthritis population. Therefore, the increasing prevalence of autoimmune diseases is driving the Polymyositis industry. The rising demand for oral drugs is expected to propel the growth of the polymyositis market going forward. Oral drugs refer to medications that are taken by mouth in the form of tablets, capsules, or liquids and are absorbed through the digestive system. The rising demand for oral drugs is attributed to their convenience, ease of administration, and patient preference for non-invasive treatments, which makes them a preferred choice over injections or other delivery methods. Polymyositis is treated with oral drugs that help reduce muscle inflammation, modulate the immune system, and enhance muscle function, thereby alleviating symptoms and preventing disease progression. For instance, in October 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based government administration, among 393,390 non-hospitalized U.S. adults aged 65 years and older, 45.9% received an oral antiviral treatment (nirmatrelvir-ritonavir or molnupiravir) within 30 days of diagnosis, with usage reported at 48.4% for individuals aged 65–74 years and 35.2% for those aged 90 years and above. Therefore, the rising demand for oral drugs is driving the growth of the polymyositis industry.

Key Players In The Global Polymyositis Market

Major companies operating in the polymyositis market are Pfizer Inc., F Hoffmann La Roche AG, Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Merck & Co. Inc., C H Boehringer Sohn AG & Co. KG, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Fresenius SE & Co. KGaA, UCB S.A., Teva Pharmaceuticals USA Inc., Kezar Life Sciences Inc., Argenx SE, Mallinckrodt Pharmaceuticals plc, Mitsubishi Tanabe Pharma Corporation, Sanofi S.A., AbbVie Inc., Eli Lilly and Company, Janssen Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., CSL Behring

Global Polymyositis Market Trends and Insights

Major companies operating in the polymyositis market are focusing on developing innovative therapies such as stem cell therapy to enhance treatment efficacy and slow disease progression. Stem cell therapy involves the use of umbilical cord-derived stem cells for regenerative treatment. These stem cells have strong immunomodulatory and anti-inflammatory properties, making them a promising option for treating autoimmune diseases such as polymyositis. For instance, in December 2024, RESTEM, a US-based clinical-stage biotechnology company, received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for its stem cell program utilizing umbilical cord outer lining stem cells (ULSCs). This program utilizes umbilical cord outer lining stem cells to treat polymyositis and Dermatomyositis by regulating the immune system and reducing muscle inflammation. The therapy has shown promising safety and efficacy in early trials, with potential to decrease steroid dependency.

Regional Outlook

North America was the largest region in the polymyositis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Polymyositis Market?

The polymyositis market consists of revenues earned by entities by providing services such as diagnosis and testing services, pharmacological treatment services, physical therapy and rehabilitation services, and occupational therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The polymyositis market also includes sales of anti-inflammatory and pain management medications, biologic therapies, intravenous immunoglobulin (IVIG) therapy, and plasmapheresis (plasma exchange) products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Polymyositis Market Report 2026?

The polymyositis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the polymyositis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.